• Explore /
  • Poster
  • / ANTICIPATE: A phase I/II, open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC).

ANTICIPATE: A phase I/II, open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC).

Abstract Video & Slides Poster

Authors

null

Matt D. Galsky

The Tisch Cancer Institute, Mount Sinai, New York, NY

Matt D. Galsky , John P. Sfakianos , Ding-Wei Ye , Mingming Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04813107

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4613)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4613

Abstract #

TPS4613

Poster Bd #

96b

Abstract Disclosures

Similar Posters

First Author: Thomas Powles

First Author: Thomas Powles

First Author: Xiao X. Wei

First Author: Xiao Yang